← Leaderboards
Raymond Scott McClelland
University Of Washington
$25,618,064
Attributed
$35,370,354
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$35,370,354 · 16
By mechanism
UM1$15,805,575 · 1
R01$14,293,997 · 7
P01$2,828,285 · 1
K24$862,595 · 1
K23$626,832 · 2
R21$458,992 · 1
Top collaborators
- Anna Wald13 shared
- Jennifer M Lund3 shared
- Joshua Kimani2 shared
- Julie M Overbaugh1 shared
Most similar at University Of Washington
Same institution · by research overlap
- Lisa E Manhart$10,223,947
- Walter E Stamm$7,096,268
- Nancy B. Kiviat$21,349,193
- Anna Wald$34,443,936
- Alison Christina Roxby$2,811,951
Others in their field
Top investigators on “United States National Institutes Of Health”
- Leonard Freedman · Leidos Biomedical Research, Inc.$816,847,401
- Sonia M Thomas · Research Triangle Institute$701,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$642,073,624
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$513,687,120
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United States National Institutes Of HealthWomanCountryKenyaFundingAreaClinicSexually Transmitted DiseasesProgramsWomen&AposResourcesAfrica South Of The SaharaParticipantCostReportingPharmaceutical PreparationsClinical TrialsSiteMultidisciplinaryPreventionBaseEvaluationFemaleInternational
Grant awards (61)
University of Washington Vaccine and Treatment Evaluation Unit$2,527,789
UM1 · FY2025 · AI
T-cell activation and exhaustion in the HIV-positive female genital tract$761,722
R01 · FY2025 · HD · contact PI
Hybrid Type-1 Effectiveness-Implementation Trial of Motivation Matters! A Theory-Based mHealth Intervention to Support Early Antiretroviral Adherence in HIV+ African Women Who Engage in Sex Work$660,772
R01 · FY2025 · MH · contact PI
University of Washington Vaccine and Treatment Evaluation Unit$2,579,381
UM1 · FY2024 · AI
T-cell activation and exhaustion in the HIV-positive female genital tract$770,346
R01 · FY2024 · HD · contact PI
Hybrid Type-1 Effectiveness-Implementation Trial of Motivation Matters! A Theory-Based mHealth Intervention to Support Early Antiretroviral Adherence in HIV+ African Women Who Engage in Sex Work$665,326
R01 · FY2024 · MH · contact PI
University of Washington Vaccine and Treatment Evaluation Unit$1,863,350
UM1 · FY2023 · AI
T-cell activation and exhaustion in the HIV-positive female genital tract$810,839
R01 · FY2023 · HD · contact PI
Impact of the vaginal microbiome on Chlamydia trachomatis acquisition$640,548
R01 · FY2023 · AI · contact PI
University of Washington Vaccine and Treatment Evaluation Unit$1,561,928
UM1 · FY2022 · AI
University of Washington Vaccine and Treatment Evaluation Unit$621,600
UM1 · FY2022 · AI
University of Washington Vaccine and Treatment Evaluation Unit$345,560
UM1 · FY2022 · AI
University of Washington Vaccine and Treatment Evaluation Unit$111,108
UM1 · FY2022 · AI
University of Washington Vaccine and Treatment Evaluation Unit$2,516,717
UM1 · FY2021 · AI
University of Washington Vaccine and Treatment Evaluation Unit - DMID 21-0012$1,259,301
UM1 · FY2021 · AI
University of Washington Vaccine and Treatment Evaluation Unit -- DMID 20-0034$734,126
UM1 · FY2021 · AI
University of Washington Vaccine and Treatment Evaluation Unit$625,251
UM1 · FY2021 · AI
University of Washington Vaccine and Treatment Evaluation Unit$427,640
UM1 · FY2021 · AI
University of Washington Vaccine and Treatment Evaluation Unit$631,824
UM1 · FY2020 · AI
Impact of periconceptual vaginal microbiota on women's risk of preterm birth$536,884
R01 · FY2020 · HD · contact PI
RCT of an Implementation Science Tool to Integrate HIV testing into Family Planning Services$177,034
K24 · FY2020 · HD · contact PI
Impact of periconceptual vaginal microbiota on women's risk of preterm birth$555,635
R01 · FY2019 · HD · contact PI
RCT of an Implementation Science Tool to Integrate HIV testing into Family Planning Services$177,034
K24 · FY2019 · HD · contact PI
Impact of periconceptual vaginal microbiota on women's risk of preterm birth$543,285
R01 · FY2018 · HD · contact PI
Impact of periconceptual vaginal microbiota on women's risk of preterm birth$516,102
R01 · FY2018 · HD · contact PI
RCT of an Implementation Science Tool to Integrate HIV testing into Family Planning Services$177,034
K24 · FY2018 · HD · contact PI
CFAR Sub-Saharan Africa Working Group Symposium 2019$74,000
R13 · FY2018 · HD · contact PI
Mombasa HIV/STD Research Site 25th Anniversary Symposium$30,000
R13 · FY2018 · AI · contact PI
Impact of periconceptual vaginal microbiota on women's risk of preterm birth$547,435
R01 · FY2017 · HD · contact PI
RCT of an Implementation Science Tool to Integrate HIV testing into Family Planning Services$177,034
K24 · FY2017 · HD · contact PI
Impact of periconceptual vaginal microbiota on women's risk of preterm birth$586,719
R01 · FY2016 · HD · contact PI
Women's Life Events & HIV Transmission Potential: A Multidisciplinary Study$412,113
R01 · FY2016 · HD · contact PI
Motivation matters! RCT of theory-based, SMS to support TASP in high-risk women$193,670
R21 · FY2016 · MH · contact PI
RCT of an Implementation Science Tool to Integrate HIV testing into Family Planning Services$154,459
K24 · FY2016 · HD · contact PI
Women's Life Events & HIV Transmission Potential: A Multidisciplinary Study$414,522
R01 · FY2015 · HD · contact PI
Motivation matters! RCT of theory-based, SMS to support TASP in high-risk women$194,214
R21 · FY2015 · MH · contact PI
Impact of social network characteristics on the efficacy of an interactive SMS intervention to improve ART adherence and viral load suppression in high-risk women in Mombasa, Kenya$71,108
R21 · FY2015 · MH · contact PI
Administrative supplement to Lifecourse study for replacement freezer$30,174
R01 · FY2015 · HD · contact PI
Impact of suppressive antimicrobial therapy on the vaginal microbiota and BV$659,855
R01 · FY2014 · AI · contact PI
Women's Life Events & HIV Transmission Potential: A Multidisciplinary Study$413,248
R01 · FY2014 · HD · contact PI
Impact of suppressive antimicrobial therapy on the vaginal microbiota and BV$533,080
R01 · FY2013 · AI · contact PI
Vaginal Health and the Risk of HIV-1 Acquistion in Kenyan Women$529,785
P01 · FY2013 · HD · contact PI
Women's Life Events & HIV Transmission Potential: A Multidisciplinary Study$403,470
R01 · FY2013 · HD · contact PI
Impact of suppressive antimicrobial therapy on the vaginal microbiota and BV$589,106
R01 · FY2012 · AI · contact PI
Vaginal Health and the Risk of HIV-1 Acquistion in Kenyan Women$573,045
P01 · FY2012 · HD · contact PI
Women's Life Events & HIV Transmission Potential: A Multidisciplinary Study$438,624
R01 · FY2012 · HD · contact PI
Vaginal Health and the Risk of HIV-1 Acquistion in Kenyan Women$578,045
P01 · FY2011 · HD · contact PI
Antiretroviral Therapy and HIV-1 Infectivity in Women$390,078
R56 · FY2011 · AI · contact PI
Vaginal Health and the Risk of HIV-1 Acquistion in Kenyan Women$559,139
P01 · FY2010 · HD · contact PI
Antiretroviral Therapy and HIV-1 Infectivity in Women$120,591
R01 · FY2010 · AI · contact PI
Vaginal Health and the Risk of HIV-1 Acquistion in Kenyan Women$588,271
P01 · FY2009 · HD · contact PI
Antiretroviral Therapy and HIV-1 Infectivity in Women$538,698
R01 · FY2009 · AI · contact PI
Antiretroviral Therapy and HIV-1 Infectivity in Women$553,853
R01 · FY2008 · AI · contact PI
Antiretroviral Therapy and HIV-1 Infectivity in Women$549,670
R01 · FY2007 · AI · contact PI
Antiretroviral Therapy and HIV-1 Infectivity in Women$548,094
R01 · FY2006 · AI · contact PI
Antiretroviral Therapy and HIV-1 Infectivity in Women$493,286
R01 · FY2005 · AI
REDUCING VAGINAL INFECTIONS IN WOMEN AT RISK FOR HIV-1$125,253
K23 · FY2005 · AI
REDUCING VAGINAL INFECTIONS IN WOMEN AT RISK FOR HIV-1$125,253
K23 · FY2004 · AI
REDUCING VAGINAL INFECTIONS IN WOMEN AT RISK FOR HIV-1$125,253
K23 · FY2003 · AI
REDUCING VAGINAL INFECTIONS IN WOMEN AT RISK FOR HIV-1$125,253
K23 · FY2002 · AI
REDUCING VAGINAL INFECTIONS IN WOMEN AT RISK FOR HIV-1$125,820
K23 · FY2001 · HD